Temasek Holdings (Private) Limited sold 1.5 million shares of Oconvision Biotech (01477.HK) common shares worth approximately HK$10.753 million
On May 16, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on May 16, Temasek Holdings (Private) Limited sold $1.5 million shares worth HK$10.753 million at an average price of HK$7.1702 per share on May 10. After the sale, the latest number of shares held by Temasek Holdings (Private) Limited was 47.1934 million shares, and the good position ratio dropped from 7.00% to 6.7
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
歐康維視生物-B:二零二三年年報
Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug
Ocumension Therapeutics' (HKG:1477) new drug for treating postoperative inflammation successfully achieved the expected results in a phase III clinical trial, according to a Monday filing with the Hon
Okanvision Bio-B (01477.HK): Phase III clinical trial of OT-502 in China reached the main end
Gelonghui, April 15 | Okanvision Bio-B (01477.HK) announced that OT-502 (DEXYCU, dexamethasone implant), a new drug for treating post-operative inflammatory indications, has successfully reached the expected main efficacy endpoint of its phase III clinical trial. That is, on day 8, the proportion of subjects with anterior atrial atrial cell clearance (ACC grade 0) in the treatment group with dexamethasone implants was significantly higher than in the placebo group, proving that this product is safe and effective in controlling inflammation after cataract surgery. The company expects to submit an OT-502 new drug application to the Drug Evaluation Center of the China National Drug Administration in the near future. O
Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon
Ocumension Therapeutics (HKG:1477) said its new drug completed clinical phase III and will soon apply for a new drug registration, according to a Monday filing on the Hong Kong bourse. The drug, OT-70
Okanvision Bio-B (01477.HK): OT-702 phase III clinical trial completed in China
Gelonghui, April 8 | Okanvision Bio-B (01477.HK) announced that the phase III clinical trial of OT-702 (abercip intraocular injection solution, EYLEA biosimilar) has been successfully completed in China. OT-702 was jointly developed by the Group and its partner Shandong Boan Biotechnology Co., Ltd. (“Boan Biotech”) (the company's shares are listed on the Hong Kong Stock Exchange Limited (stock code: 6955)). The phase III clinical study of OT-702 was carried out in cooperation between the two parties. The application for the new drug will be reviewed by the China Drug Administration in the near future
Okanvision Bio-B (01477.HK): 2023 results meet expectations and expect recent R&D milestones
The 2023 revenue is in line with our expectations. The company announced its 2023 results: revenue of 246 million yuan, up 55.0% year on year; net loss to mother of 380 million yuan, which is narrower than last year, in line with our expectations. Trending products
Ocumension Therapeutics' Loss for 2023 Narrows; Shares Down 4%
Ocumension Therapeutics (HKG:1477) booked a loss of 379.8 million yuan for the year ended Dec. 31, 2023, compared with a loss of 402.6 million yuan in the year-ago period, according to a filing with t
Okanvision Bio-B (01477.HK) annual revenue increased by 55.0% to 246 million yuan
Gelonghui, March 21 | Okanvision Bio-B (01477.HK) announced that for the year ended December 31, 2023, the company's revenue increased by 55.0% to RMB 246.4 million, mainly due to a sharp increase in revenue from sales of ophthalmic products and pharmaceutical product promotion services. For the year ended 31 December 2023, the company's loss was RMB 379.8 million, down 5.7% from RMB 402.6 million for the year ended 31 December 2022, mainly due to the increase in gross profit of RMB 41.4 million and R&D compared with last year
OCUMENSION-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Ocumension Therapeutics' Phase 2 Trial for Dry Eye Treatment Meets Clinical Endpoints
Ocumension Therapeutics' (HKG:1477) phase 2 clinical trial for its OT-202 treatment for dry eye achieved primary clinical endpoints, according to a Thursday filing with the Hong Kong bourse. During th
OT-202, the first novel drug of its kind developed in-house by Okanvision Bio-B (01477) to treat dry eye, has reached the main clinical end of phase II clinical trials
Okanvision Bio-B (01477) announced OT, the first novel drug of its kind developed by the company to treat dry eye syndrome...
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Changes in Hong Kong stocks | Okanvision Bio-B (01477) is now up more than 7% Sinqi Eye Medication Atropine Eye Drops Approved Clinical Trials of Listed Companies' Products Previously Approved
Okanvision Bio-B (01477) is now up more than 7%. As of press release, it is up 7.57% to HK$5.97, with a turnover of HK$10.8087 million.
Guojin Securities: The first domestic eye drops to slow myopia in children have been approved for sale and are expected to be released quickly with a first-mover advantage
On March 11, according to the official website of the State Drug Administration, Sinqi Pharmaceutical (300573.SZ) atropine sulfate eye drops were approved for marketing on March 5, 2024.
Okanvision Bio-B (01477.HK) held a board meeting on March 21 to approve annual results
Glonghui March 7 | Okanvision Bio-B (01477.HK) announced that the company will hold a board meeting on March 21, 2024 (Thursday) to consider and approve (among other things) the results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and consider recommending payment of a final dividend (if any).
OCUMENSION-B: DATE OF BOARD MEETING
No Data